期刊文献+

免疫检查点与常见头颈部鳞状细胞癌的临床研究现状 被引量:5

Clinical research on immune checkpoint and head and neck squamous cell carcinoma
原文传递
导出
摘要 近年来,T细胞免疫检查点信号通路因参与了肿瘤免疫逃逸机制而成为了新的研究热点.T细胞免疫检查点及其配体的表达不仅调控着肿瘤的免疫微环境,也和恶性肿瘤的发生、分期及预后密切相关,还有望成为肿瘤复发和转移的生物学监测指标.目前免疫检查点抑制剂在包括头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)在内的多种实体肿瘤中开展了大量的临床试验,并展示出良好的治疗前景,已经成为肿瘤免疫治疗的新靶点.本文将针对T细胞免疫检查点相关基因及蛋白在HNSCC免疫微环境中的表达、与临床预后相关性及其抑制剂在HNSCC临床免疫治疗中的应用现状作一综述. T cell immune checkpoint pathways contribute to tumor immune escape.Many studies have shown that immune checkpoint is demonstrably correlated with tumor grade or prognosis in several types of malignancies and immune checkpoint has become a new biological index for tumor detection and prognosis.Immune checkpoint inhibitors have shown promising tumor outcomes in clinical trials for some advanced solid tumors and it will become a new target for cancer immunotherapy.In this review we will explore the correlation between expressions of immune checkpoint-associated genes and proteins in immune microenviroment and prognosis of head and neck squamous cell carcinoma,and specifically will discuss how this pathway can be manipulated with immune therapeutic drugs.
出处 《中华耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2017年第9期717-720,共4页 Chinese Journal of Otorhinolaryngology Head and Neck Surgery
基金 国家自然科学基金青年基金(81502348) 国家自然科学基金(81572653) 吉林省科技厅青年基金(20150520042JH) 吉林省自然科学基金(20160101039JC)
关键词 头颈部肿瘤 鳞状细胞 CTLA-4 PDl/PDLl分子 免疫检查点 免疫治疗 Head and neck neoplasms Carcinoma,squamous cell PD1/PDL1 molecular Immune checkpoint Immunotherapy
  • 相关文献

参考文献5

二级参考文献24

  • 1CHEN L. Co-inhibitory molecules of the BT-CD28 family in the control of T cell immunity[J].Nat Rev Immunol, 2004,4 : 336 -- 347. 被引量:1
  • 2NURIEVA R, THOMAS S, NGUYEN T, et al. T cell tolerance or function is determined by combinatorial eostimulatory signals [J]. EMBO J,2006, 25: 2623--2633. 被引量:1
  • 3OKAZAKI T, HONJO T. The PD-1/PD-L pathway in immunological tolerance [J]. Trends Immunol, 2006,27:195--201. 被引量:1
  • 4PARDOLL D M. Spinning molecular immunology into successful immunotherapy[J]. Nat Rev Immunol, 2002,2:227--238. 被引量:1
  • 5FINGER I. R, PU J Y, WASSERMAN R, et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors[J].Gene, 1997,197 : 177-- 187. 被引量:1
  • 6LATCHMAN Y, WOOD C R, TATYANA C, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001,2 : 261 -- 267. 被引量:1
  • 7SHARPE A H, FREEMAN G J. The B7-CD28 su perfamily[J]. Nat RevImmunol,2002, 2:116- 126. 被引量:1
  • 8DONG H, ZHU G, TAMADA K, et al. B7-H1,a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [J]. Nat Med, 1999,5:1365-1369. 被引量:1
  • 9LATCHMAN Y E, LIANG S C,WU Y,et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells ,and host tissues negatively regulates T cells[J]. Proc Nat Acad Sci USA,2004,101: 10691-10696. 被引量:1
  • 10LIM D Y, TANAKA Y, IWASAKI M, et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors [J]. Proc Natl Acad Sci USA,2008,105:3011-3016. 被引量:1

共引文献46

同被引文献38

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部